Payment overview · 2025
General Payments
$432.98
21 reported records · 12 companies
Healthcare provider profile · identity verified
Jared Henderson, MD
Allopathic & Osteopathic Physicians|Family Medicine · TWIN FALLS, ID · NPI 1336597152
Verified facts
What the public records show
CMS Open Payments records show Jared Henderson, MD received $432.98 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.03 | 33.5% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.36 | 11.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.54 | 11.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.33 | 7.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.89 | 5.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.48 | 5.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.99 | 5.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.37 | 4.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.31 | 4.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.13 | 4.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.88 | 3.9% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $14.67 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.98 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $145.03 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $145.03 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $49.54 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.33 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 63 |
| Omeprazole | Omeprazole | 207 | 59 |
| Metformin Hcl Er | Metformin Hcl | 150 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 40 |
| Ozempic | Semaglutide | 141 | 26 |
| Trazodone Hcl | Trazodone Hcl | 137 | 42 |
| Lisinopril | Lisinopril | 121 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 28 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 97 | 29 |
| Potassium Chloride | Potassium Chloride | 97 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 29 |
| Furosemide | Furosemide | 88 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 30 |
| Gabapentin | Gabapentin | 84 | 30 |
| Losartan Potassium | Losartan Potassium | 83 | 25 |
| Eliquis | Apixaban | 79 | 21 |
| Spironolactone | Spironolactone | 77 | 16 |
| Jardiance | Empagliflozin | 68 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 68 | 19 |
| Finasteride | Finasteride | 66 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 21 |
| Tramadol Hcl | Tramadol Hcl | 65 | 21 |
| Warfarin Sodium | Warfarin Sodium | 63 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 24 |
| Carvedilol | Carvedilol | 57 | 15 |
| Metformin Hcl | Metformin Hcl | 56 | 20 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Famotidine | Famotidine | 54 | 14 |
| Sertraline Hcl | Sertraline Hcl | 51 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 19 |
| Pregabalin | Pregabalin | 49 | 11 |
| Alendronate Sodium | Alendronate Sodium | 48 | 18 |
| Meloxicam | Meloxicam | 47 | 23 |
| Allopurinol | Allopurinol | 45 | 14 |
| Simvastatin | Simvastatin | 45 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 11 |
| Glipizide | Glipizide | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | 14 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Atenolol | Atenolol | 30 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Prednisone | Prednisone | 29 | 13 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Estradiol | Estradiol | 25 | 13 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 12 |
| Telmisartan | Telmisartan | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Azithromycin | Azithromycin | 19 | 14 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.98 · 21 records | Novo Nordisk Inc | ABRYSVO, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, LEQVIO, M-M-R II, Ozempic, PONVORY, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error